GlobeNewswire (May 1, 2013)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
552 people get OCLS articles and Market Currents by email alert.
Get email alerts on OCLS »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
GlobeNewswire (Apr 10, 2013)
-
-
-
GlobeNewswire (Mar 28, 2013)
-
GlobeNewswire (Mar 26, 2013)
-
GlobeNewswire (Mar 20, 2013)
-
GlobeNewswire (Mar 14, 2013)
-
GlobeNewswire (Mar 12, 2013)
-
GlobeNewswire (Mar 7, 2013)
-
-
GlobeNewswire (Feb 13, 2013)
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
-
Oculus Launches Wound Treatment Product in ChinaChinaBio Today • Sun, Sep 14, 2008 -
-
Oculus Receives SFDA Approval for Wound TreatmentChinaBio Today • Tue, Apr 1, 2008
-
Oculus Innovative Sciences IPO Analysis: Six Month ReviewPharmaTracker • Mon, Aug 13, 2007
-
IPO Watch: Oculus Seeks Foothold In Wound HealingCentient Biotech Investor • Thu, Jan 25, 2007 -
New Terms for Oculus Innovative Sciences IPOSA Editor Abbi Adest • Sun, Jan 14, 2007
-
-
-
China Biotech In Review: Deals, Trials And RegulationsChinaBio Today • Sun, Jul 15, 2012
-
-
-
A Look at 5 Stocks in the Green WednesdayAlex Shadunsky • Thu, Jul 28, 2011 -
-
China Biotech Week in Review: CROs ConsolidatingChinaBio Today • Sun, Nov 22, 2009
-
Oculus Wins China Approval for Animal Wound ProductChinaBio Today • Tue, Nov 17, 2009
-
-
-
-
-
China Biopharma Week in Review: Broad Views, Individual CompaniesChinaBio Today • Sun, Sep 14, 2008
-
China Biotech in Review: A Week of CollaborationsChinaBio Today • Sun, Jun 29, 2008
-
Oculus to Use Bayer for Approval of Wound Treatment in AnimalsChinaBio Today • Wed, Jun 25, 2008
-
Following the China Biopharma BeatChinaBio Today • Sun, May 25, 2008
-
Downturn in China Biotech Stocks Shows No Impact on ActivityChinaBio Today • Mon, Apr 7, 2008
-
-
-
GlobeNewswire (Apr 10, 2013)
-
GlobeNewswire (Mar 28, 2013)
-
GlobeNewswire (Mar 26, 2013)
-
GlobeNewswire (Mar 20, 2013)
-
GlobeNewswire (Mar 14, 2013)
-
GlobeNewswire (Mar 12, 2013)
-
GlobeNewswire (Mar 7, 2013)
-
at MarketWatch.com (Mar 7, 2013)
-
GlobeNewswire (Feb 13, 2013)
-
Oculus Innovative Sciences Announces Fiscal Third Quarter 2013 Financial Results and Conference CallGlobeNewswire (Jan 31, 2013)
-
GlobeNewswire (Jan 28, 2013)
-
GlobeNewswire (Jan 10, 2013)
OCLS vs. ETF Alternatives
Company Description
Currently, there's no company description for OCLS.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
-
Wednesday, May 15, 12:45 PM
Midday top 10 gainers: MFLR +64%. CHCI +33%. NYNY +24%. GPRC +24%. EVK +22%. DVR +21%. DQ +19%. GBR +19%. MRIN +17%. INSM +17%.
Midday top 10 losers: HOTR -16%. XONE -12%. CALI -11%. CSC -10%. UAMY -10%. PRMW -10%. IIJI -9%. ANV -9%. OCLS -9%. CHLN -9%. 1 Comment [On the Move] -
Wednesday, May 8, 12:53 PM
Midday top 10 gainers: TRMD +68%. SYNM +35%. AFFY +35%. ALXA +25%. CSPI +21%. PSE +21%. NBG +20%. WBMD +18%. SCOK +17%. EA +16%.
Midday top 10 losers: FIO -25%. OCLR -23%. LIOX -18%. VCLK -17%. AXLL -16%. OCLS -15%. BTH -15%. SALM -13%. ACFC -12%. SNTA -12%. Comment! [On the Move] - Wednesday, April 10, 2:40 PM Oculus Innovative Sciences (OCLS) says its partner Dyamed Biotech is initiating rollout of five new Microcyn Technology-based products in Singapore and Malaysia, both in the hospital and consumer markets. The five products, which include Dermacyn BabyGuard, Dermacyn DermaGuard, Dermacyn SkinGuard Solution, Dermacyn SkinGuard Hydrogel and Dermacyn Wound Care Hydrogel, will be rolled out sequentially with all products commercialized by year's end. 1 Comment [Healthcare]
- Tuesday, March 26, 2:48 PM Shares of Oculus Innovative Sciences (OCLS +3%) tick higher today after the company says it's been granted a CE Mark reclassification for its European formulation Dermacyn Wound Care. The newest indication is for the moistening of acute and chronic wounds and reducing the amount of microorganisms in the wound area. Additionally, the actives in Dermacyn are classified in Europe as medicinal substances that may have a local antimicrobial effect. 2 Comments [Healthcare, On the Move]
- Thursday, March 7, 10:22 AM Shares of Oculus Innovative Sciences (OCLS -22%) get hammered after pricing a 7.5M share offering at $0.40, a 25% discount to yesterday's closing price. The company announced its intention to offer stock after yesterday's close, but didn't detail the number of shares or the price. The commercial healthcare company currently has around 37.4M shares outstanding. Comment! [Healthcare, On the Move]
- Wednesday, March 6, 4:13 PM Oculus Innovative Sciences (OCLS) announces a public stock offering. It intends to use the net proceeds for the repayment of debt and to retire a portion of common stock previously issued to its lenders. The size and terms of the offering haven't been disclosed. Aegis Capital is acting as sole book-running manager. Shares -7.4% AH. Comment! [Healthcare, On the Move]
- Wednesday, February 13, 6:40 PM Oculus Innovative Sciences (OCLS): FQ3 EPS of -$0.05 beats by $0.03. Revenue of $3.5M (+27% Y/Y) beats by $0.22M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Thursday, December 27, 2012, 11:23 AM Oculus Innovative Sciences (OCLS +5.3%) says it's been issued a new patent for the use of Microcyn Technology in the treatment of skin ulcers. Microcyn Technology can be delivered to skin ulcers via washing, irrigation and soaking or through application of a wound dressing saturated in the treatment. Comment! [Healthcare, On the Move]
-
hitekmastr
$OCLS recently received an unsubstantiated hit by an online pundit who posted some misleading information, which dropped the stock. - View all 0 replies
-
- View all 1 replies
-
-
- View all 0 replies
LATEST REPLIES
-
- View all 1 replies
-